Skip to Content
Merck
All Photos(1)

Key Documents

Z101

Sigma-Aldrich

Zimelidine dihydrochloride

solid

Synonym(s):

(Z)-3-(4-Bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-2-propen-1-amine dihydrochloride

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H17BrN2 · 2HCl
CAS Number:
Molecular Weight:
390.15
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

form

solid

color

white

solubility

0.1 M HCl: 45 mg/mL
H2O: 66 mg/mL

originator

AstraZeneca

SMILES string

Cl[H].Cl[H].[H]\C(CN(C)C)=C(/c1ccc(Br)cc1)c2cccnc2

InChI

1S/C16H17BrN2.2ClH/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13;;/h3-10,12H,11H2,1-2H3;2*1H/b16-9-;;

InChI key

CXGURXWCQYHDIR-ULPVBNQHSA-N

Application

Zimelidine dihydrochloride has been used as a serotonin transport inhibitor to study its inhibitory role in the uptake of exogenous serotonin by bipolar cells.

Biochem/physiol Actions

Zimelidine, an antidepressant, is a specific 5-hydroxytryptamine (5-HT) reuptake inhibitor, that can be used in treating phobic anxiety. It is very effective and can be tolerated well in elderly individuals. This serotonin transport inhibitor is less likely than other antidepressants to have cardiovascular side effects. Unlike other tricyclic antidepressants, Zimelidine might promote weight loss but not weight gain.

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold with the permission of Astra AB.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R W Fuller
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 45, 167-204 (1995-01-01)
Fluoxetine, zimelidine, sertraline, paroxetine, fluvoxamine, indalpine and citalopram are the selective inhibitors of serotonin uptake that have been most widely studied. Some of these compounds are or have been used clinically in the treatment of mental depression, obsessive-compulsive disorder and
T Egashira et al.
Japanese journal of pharmacology, 81(1), 115-121 (1999-12-02)
The effects of the antidepressant drugs zimeldine, imipramine, maprotiline or nomifensine on mitochondrial monoamine oxidase (MAO) activity in mouse, rat, dog and monkey brains were compared in vitro. Mouse, rat, dog and monkey brain MAO-B activities were inhibited by zimeldine
M G Frank et al.
Brain research, 768(1-2), 287-293 (1997-11-22)
Chronic postnatal exposure to clomipramine (CMI), a monoamine uptake inhibitor, results in persistent alterations in adult rat REM sleep. These effects have been ascribed to CMI's ability to block neonatal active sleep (AS). However, these effects have not been obtained
S Esteban et al.
Naunyn-Schmiedeberg's archives of pharmacology, 360(2), 135-143 (1999-09-24)
The effects of antidepressant drugs on the synthesis of noradrenaline and serotonin (5-HT) were assessed using the accumulation of 3,4-dihydroxyphenylalanine (dopa) and 5-hydroxytryptophan (5-HTP) after decarboxylase inhibition as a measure of the rate of tyrosine and tryptophan hydroxylation in the
Yoshiko Okai et al.
Journal of pharmacological and toxicological methods, 105, 106893-106893 (2020-07-04)
Drug-induced inotropic change is a risk factor in drug development; thus, de-risking is desired in the early stages of drug development. Unlike proarrhythmic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), few in vitro models were validated to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service